Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other (expense) income, net | (15,040) | 38,061 | (30,299) | (45,071) |
| (Loss) income before income tax expense (benefit) | (1,749) | 153,638 | 341,425 | (229,880) |
| Income tax expense (benefit) | 3,141 | (43,254) | 15,356 | 20,736 |
| Net (loss) income | $(4,890) | $196,892 | $326,069 | $(250,616) |
| Other comprehensive (loss) income: | ||||
| Unrealized (losses) gains on investments, net of tax | (444) | (85) | (837) | 167 |
| Total other comprehensive (loss) income | (444) | (85) | (837) | 167 |
| Comprehensive (loss) income | $(5,334) | $196,807 | $325,232 | $(250,449) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — net income loss?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — net income loss of -$4.89M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — net income loss changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — net income loss decreased by 102.5% year-over-year, from $196.89M to -$4.89M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — net income loss?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — net income loss has grown at a 0.5% compound annual growth rate (CAGR), from -$703.49M to -$713.41M.
- What does business segments — net income loss mean?
- The final bottom-line financial result for the segment after all revenues, operating expenses, taxes, and non-operating items are accounted for. This metric serves as the primary indicator of the segment's overall profitability and economic viability. It captures the net impact of all business activities within this specific segment.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude